Login to Your Account

Clinic Roundup

Friday, March 30, 2012

• Isis Pharmaceuticals Inc., of Carlsbad, Calif., and Genzyme Corp., of Cambridge, Mass., a unit of Sanofi SA, reported two-year data from a Phase III long-term extension study showing that Kynamro (mipomersen) maintained robust reductions in LDL-C in patients, as well as reductions in all other Apo B-containing atherogenic lipoproteins measured, with a safety profile consistent with the Phase III studies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription